Rx Propellant Announces US$ 100 Mn Investment to Develop Integrated Large-Format Life Sciences Campus in Genome Valley, Hyderabad

Rx Propellant has announced an investment of USD 100 Mn to develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India’s life sciences ecosystem. The project will comprise development of more than 1 million square feet of advanced laboratory infrastructure to be delivered in phases over the next six years.

Planned as a single, integrated campus with multiple blocks, the project will be the largest life sciences campus in Genome Valley designed for corporations looking to lease buildings with well-managed resilient support infrastructure. The campus will cater to Indian and global life sciences companies seeking scalable and quality infrastructure for R&D and allied operations, delivering institutional-grade laboratory spaces, bringing together fully compliant buildings and high-performance electromechanical services in a robust design.

Ashish Singh, CEO and Managing Director, Rx Propellant, said, “India’s life sciences sector is entering a phase of decisive scale-up, and buildings and infrastructure solutions must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley, Hyderabad as a long-term anchor for global and domestic R&D. Rx Propellant already has an established track record in Genome Valley, with its 1GV and 3GV campuses already 100% leased, hosting a mix of marquee global and Indian life sciences companies. Sustained demand for high quality buildings in Genome Valley provides a strong foundation for our next phase of growth as we continue delivering high-quality infrastructure at scale, helping our customers expand with confidence and continuity.”

Beyond Hyderabad, Rx Propellant is also developing Navi Mumbai Research District (NMRD) spread over a site of 16 acres, planned as Mumbai’s largest cohesive ecosystem for science and research. Together, these investments reflect Rx Propellant’s strategy of creating long-term, institutional-quality science and R&D infrastructure across India’s most important innovation clusters.

Sustainability remains a core pillar of Rx Propellant’s development philosophy. All existing campuses in its portfolio are planned in line with globally recognised green building standards, with LEED and IFC EDGE certifications embedded in design and operations. This approach ensures long-term resource efficiency and reduces environmental impact across the asset lifecycle.

Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said, “High-quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. With increasing global interest in research, development and manufacturing partnerships within India, this investment underscores our conviction in India and in Hyderabad’s role as a leading R&D hub. Expanding Rx Propellant’s footprint in Genome Valley is a strategic step toward building a network of world-class life sciences campuses in India that can support companies at every stage of their growth journey from R&D to manufacturing.”